# ARA-290 Peptide, Answered: Top Questions Reviewed

**By TelosRX Editorial Team** · 2026-11-11

**The ARA-290 peptide (cibinetide) is an investigational 11-amino-acid peptide built from erythropoietin. Small trials studied it for nerve pain and nerve fiber loss. It is not FDA-approved. [TelosRX](https://telosrx.com) answers the top questions.**

The ARA-290 peptide went from obscure to trending almost overnight. Search interest for "ARA-290" spiked over the past month. Most of what you'll find online is sales copy. Very little of it tells you what the studies actually measured.

Below, the clinical team that reviews TelosRX peptide protocols answers the questions people ask most. Each answer points to a source you can check. None of it is a promise of results, and any peptide prescription is subject to medical approval by a licensed provider.

## ARA-290 at a Glance

| Question | Short answer |
| --- | --- |
| Other name | Cibinetide |
| Size | 11 amino acids |
| Built from | Helix B of erythropoietin (EPO), the red-blood-cell hormone |
| Target | The "innate repair receptor," a tissue-protective receptor complex |
| Raises red blood cells? | No, it was designed not to |
| Main human studies | Small phase 2 trials in sarcoidosis nerve loss and type 2 diabetes neuropathy |
| Route in trials | Injection (under the skin or into a vein) |
| FDA status | Not FDA-approved for any use |

## What is the ARA-290 peptide?

ARA-290 is a lab-made peptide modeled on one small region of erythropoietin, called helix B. Erythropoietin (EPO) is the hormone that tells your body to make red blood cells.

EPO also protects tissue under stress. But it raises blood counts and clotting risk, which limits its use. ARA-290 was engineered to keep the protective signal and drop the blood-building one ([Brines et al., Mol Med, 2015](https://pubmed.ncbi.nlm.nih.gov/25387363/)).

## How does ARA-290 work?

It binds the **innate repair receptor**. That's a pairing of the EPO receptor with a partner called the beta-common receptor (CD131). This complex switches on during injury and inflammation.

When activated in lab and animal models, the receptor dampens inflammation and supports tissue repair. The standard EPO receptor that drives red blood cell production is a different setup. That's why ARA-290 doesn't act like EPO in the blood.

## What did the type 2 diabetes trial find?

A phase 2, placebo-controlled study enrolled people with type 2 diabetes and nerve symptoms. They took 4 mg of ARA-290 under the skin daily for 28 days ([Brines et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25387363/)). Researchers followed them for 56 days.

-   **Blood sugar:** HbA1c (a 3-month sugar average) improved in the ARA-290 group.
-   **Lipids:** cholesterol profiles improved over the observation period.
-   **Nerve symptoms:** neuropathic symptom scores improved on a standard questionnaire.
-   **Nerve fibers:** people who started with low corneal nerve fiber density saw an increase. Placebo did not.
-   **Safety:** the authors reported no safety issues in this short trial.

It's a promising signal. It's also one small, short study. That's not enough to call it proven.

## What did the sarcoidosis trials find?

Sarcoidosis is an inflammatory disease. Some patients lose small nerve fibers and develop burning pain. Researchers chose it as a test case for ARA-290.

A randomized trial published in 2017 tested cibinetide for 28 days. It reported significantly more small nerve fibers in the cornea and skin ([Culver et al., IOVS, 2017](https://pubmed.ncbi.nlm.nih.gov/28475703/)). The authors called this consistent with a possible disease-modifying effect. An earlier, smaller trial also reported symptom improvement.

You can see the design of one of these studies in the [ClinicalTrials.gov registry entry](https://clinicaltrials.gov/study/NCT02039687).

## Why do researchers look at the cornea?

Your cornea is packed with tiny nerve fibers. A special microscope (corneal confocal microscopy) can photograph them without a biopsy. That makes the eye a window into small-nerve health elsewhere in the body.

It's a clever, objective marker. But a change in nerve counts doesn't always mean a change in how someone feels day to day.

## What does the animal research show?

Preclinical research in rats reported long-lasting relief of neuropathic pain after ARA-290. One line of work linked this to calmer microglia, the immune cells of the spinal cord.

Animal findings help explain mechanism. They don't predict human dose, benefit or safety. Read them as background, not evidence of what you'd experience.

## Is ARA-290 FDA-approved?

**No.** ARA-290 is not FDA-approved for any condition. It remains an investigational compound. No country we're aware of has it on the market as an approved drug.

Products sold online as "research peptides" are labeled not for human use. Purity, sterility and labeled dose are often unverified. That's a real risk, not a technicality.

## Is ARA-290 safe?

The published trials were short, usually about four weeks, and small. Within those limits, investigators did not report serious safety signals. That's encouraging, but it isn't long-term safety data.

Open questions include:

-   Effects of use beyond a few weeks
-   Safety in people with cancer history, since EPO-pathway biology is studied in tumor growth
-   Interactions with other medications
-   Use in pregnancy, which hasn't been studied

A licensed provider should review your history before you consider any investigational peptide.

## How was ARA-290 given in studies?

Human trials used injections, either under the skin or by IV infusion, over roughly four weeks. The diabetes trial used 4 mg once daily under the skin.

There is no FDA-established dose. Trial doses describe what researchers tested, not what anyone should self-administer.

## How does ARA-290 compare with other recovery peptides?

People often line ARA-290 up against BPC-157, TB-500 and thymosin alpha-1. They're very different compounds.

-   **ARA-290:** EPO-derived, targets the innate repair receptor, studied mainly for small-nerve damage.
-   **BPC-157:** gastric-protein fragment, studied mostly in animal tendon and gut models.
-   **Thymosin alpha-1:** immune-modulating peptide. See our review of [thymosin alpha-1 benefits](https://www.telosrx.com/blogs/peptides/thymosin-alpha-1-benefits-research).

Exploring recovery-focused peptides with medical oversight? [Learn about the TelosRX BPC-157 program](https://www.telosrx.com/pages/bpc-157). BPC-157 is a compounded peptide that is not FDA-approved, and access is subject to medical approval by a licensed provider through our asynchronous online intake.

## Who should talk to a provider first?

Honestly, everyone. Nerve pain has many causes, including diabetes, B12 deficiency, thyroid disease and medications. Those deserve proper testing before anyone reaches for an investigational peptide.

Not sure if peptide therapy is right for you? Our guide to [peptide therapy eligibility](https://www.telosrx.com/blogs/peptides/peptide-therapy-eligibility-criteria) explains how providers decide.

## Frequently Asked Questions

### Is ARA-290 the same as cibinetide?

Yes. Cibinetide is the official nonproprietary name for ARA-290. Both names refer to the same 11-amino-acid peptide derived from the helix B region of erythropoietin. Research papers published before about 2016 tend to use ARA 290, while later trials often use cibinetide.

### Does ARA-290 raise red blood cell counts?

It was designed not to. ARA-290 targets the innate repair receptor rather than the classic erythropoietin receptor that drives red blood cell production. Published trials describe it as nonerythropoietic. Long-term data are limited, so any use should involve provider monitoring and appropriate lab work.

### What is ARA-290 being studied for?

Human trials have focused on small nerve fiber loss and neuropathic pain, especially in sarcoidosis and type 2 diabetes. The diabetes trial also tracked blood sugar and cholesterol markers. Animal research has looked at nerve pain and inflammation. None of these uses is FDA-approved.

### How long did ARA-290 trials last?

Most published human trials gave ARA-290 for about 28 days, then followed participants for several more weeks. The type 2 diabetes study tracked outcomes over 56 days. Because studies were short and small, the long-term benefits and risks of ARA-290 remain unknown.

### Can you legally buy ARA-290 online?

ARA-290 is not FDA-approved, and products sold online are usually labeled for research use only, not for human use. Their purity, sterility and dose are often unverified. Talk with a licensed provider about evidence-based options rather than buying unregulated research chemicals.

### Is ARA-290 a peptide?

Yes. ARA-290 is a short linear peptide made of 11 amino acids, with a molecular weight of about 1,257 daltons. It is engineered from the three-dimensional structure of erythropoietin, but it is far smaller than the full hormone and behaves differently in the body.

_TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._

Start your private evaluation at [TelosRX](https://telosrx.com).

**Tags:** ARA-290 peptide, cibinetide, expert Q&A, innate repair receptor, peptide research, small fiber neuropathy

---

> Source: [Telos RX](https://www.telosrx.com/blogs/peptides/ara-290-peptide-questions-answered)
